genXone S.A.

GX1

PLGENXN00013

Pharmaceuticals

End-of-day quote Warsaw S.E. Other stock markets 18:00:00 2024-05-26 EDT			5-day change	1st Jan Change
6.14 ^PLN	+2.33%		0.00%	+14.13%

02-12	GenXone S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
02-12	GenXone S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

GenXone S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 12, 2023 at 11:10 am

genXone S.A. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported revenue was PLN 0.705568 million compared to PLN 7.32 million a year ago. Net loss was PLN 0.834987 million compared to net income of PLN 1.92 million a year ago.

Latest news about genXone S.A.

GenXone S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-12	CI
GenXone S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	02-12	CI
GenXone S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
GenXone S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
GenXone S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
GenXone S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-10	CI
GenXone S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-10	CI
GenXone S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
GenXone S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
GenXone S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
GenXone S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-02-11	CI
GenXone S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
An unknown buyer acquired 14.3% stake in genXone S.A. from Torox Eko FIZAN, fund managed by AgioFunds Towarzystwo Funduszy Inwestycyjnych S.A.	21-06-06	CI
Genxone S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	21-02-12	CI
GenXone S.A. has completed an IPO in the amount of PLN 7.3544 million.	20-08-25	CI
GenXone S.A. announced that it has received PLN 4.14 million in funding from INC S.A.	20-04-15	CI
GenXone Raises USD 1 Million in Private Placement	20-04-15	CI
Medcamp S.A. agreed additional 34% stake in genXone S.A from Torox Eko FIZAN fund managed by AgioFunds Towarzystwo Funduszy Inwestycyjnych S.A.	20-03-12	CI
GenXone S.A. has filed an IPO in the amount of PLN 4.002 million.	19-11-21	CI
Medcamp S.A. acquired 29.84% stake in GENXONE sp. z o.o. for PLN 0.39 million.	17-09-12	CI

Chart genXone S.A.

Duration

Period

More charts

Company Profile

Genxone SA is a Poland-based company, which specializes in NGS (next generation sequencing) and medical diagnostics. The Company is involved in the development and marketing of nanoforming technology in the field of science, business and medicine and cooperates as a commercial partner with Oxford Nanopore Technologies - biotechnological innovation entity.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
GENXONE S.A.	+14.13%	5.16M
MERCK KGAA	+15.93%	79.03B
KYOWA KIRIN CO. LTD.	+8.65%	8.78B
SK BIOPHARMACEUTICALS CO., LTD.	-16.43%	4.83B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+48.34%	4.65B
YUHAN CORPORATION	+2.91%	3.89B
INDIVIOR PLC	+14.90%	2.34B
BETTA PHARMACEUTICALS CO., LTD.	-26.94%	2.18B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+16.55%	2.11B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-36.25%	2B